Sunday, November 18, 2012

Abbott Labs Piramal Healthcare Transaction

To give a quick background on the deal, the various options for the deal. Post the deal, there were a lot of questions of whether the transaction reflected the best value for the shareholders. Was Piramal better off spinning of the unit to be sold into a separate market entity and having Abbott go through an open tender?

My take on this --- the offer price would have been a lot lower than the 9X EV/sales and 30X EV/EBITDA multiple that Piramal got for the unit.

 I am going to point to a third part legal and tax consulting firm that put out a report on the Abbott and Piramal deal as soon as it was done.

It was a very interesting read. (Link from Nithin Desai Associates website)


No comments:

Post a Comment